Advertisement

Trigeminal Neuralgia in Multiple Sclerosis

  • Nitasha Mishra
Chapter

Abstract

Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system (CNS), affecting more than 2 million people worldwide [1]. It is punctuated by fully or partially reversible episodes of neurologic disability, usually lasting for days or weeks. The typical syndrome at presentation include, but is not limited to, monocular visual loss due to optic neuritis, limb weakness or sensory loss due to transverse myelitis, double vision due to brain-stem dysfunction, or ataxia due to a cerebellar lesion [2]. The association of TGN and multiple sclerosis (MS) has been well-known since the end of the nineteenth century [3]; a strong association has been suggested with a 20-fold higher prevalence of TGN in this group compared to the general population [4]. A systematic review [5] suggested a prevalence of 3.8% of TGN in patients with MS. Patients of TGN due to MS have been found to have a mean age 5.5 year less than those suffering from idiopathic TGN [6].

References

  1. 1.
    GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16:877–97.CrossRefGoogle Scholar
  2. 2.
    Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389:1336–46.CrossRefGoogle Scholar
  3. 3.
    Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38:1830–4.CrossRefGoogle Scholar
  4. 4.
    Katusic S, Williams DB, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of glossopharyngeal neuralgia, Rochester, Minnesota, 1945–1984. Neuroepidemiology. 1991;10:266–75.CrossRefGoogle Scholar
  5. 5.
    Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013;154:632–42.CrossRefGoogle Scholar
  6. 6.
    Rushton JG, Olafson RA. Trigeminal neuralgia associated with multiple sclerosis. A case report. Arch Neurol. 1965;13:383–6.CrossRefGoogle Scholar
  7. 7.
    Jensen TS, Rasmussen P, Reske-Nielsen E. Association of trigeminal neuralgia with multiple sclerosis: clinical and pathological features. Acta Neurol Scand. 1982;65:182–9.CrossRefGoogle Scholar
  8. 8.
    Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995;45:1097–100.CrossRefGoogle Scholar
  9. 9.
    Sandell T, Eide PK. The effect of microvascular decompression in patients with multiple sclerosis and trigeminal neuralgia. Neurosurgery. 2010;67:749–53.CrossRefGoogle Scholar
  10. 10.
    Abhinav K, Love S, Kalantzis G, Coakham HB, Patel NK. Clinicopathological review of patients with and without multiple sclerosis treated by partial sensory rhizotomy for medically refractory trigeminal neuralgia: a 12-year retrospective study. Clin Neurol Neurosurg. 2012;114:361–5.CrossRefGoogle Scholar
  11. 11.
    Mohammad-Mohammadi A, Recinos PF, Lee JH, Elson P, Barnett GH. Surgical outcomes of trigeminal neuralgia in patients with multiple sclerosis. Neurosurgery. 2013;73:941–50.CrossRefGoogle Scholar
  12. 12.
    Broggi G, Ferroli P, Franzini A, Nazzi V, Farina L, La Mantia L, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery. 2004;55:830–8.CrossRefGoogle Scholar
  13. 13.
    Linderoth B, Hakanson S. Paroxysmal facial pain in disseminated sclerosis treated by retrogasserian glycerol injection. Acta Neurol Scand. 1989;80:341–6.CrossRefGoogle Scholar
  14. 14.
    Kanpolat Y, Berk C, Savas A, Bekar A. Percutaneous controlled radiofrequency rhizotomy in the management of patients with trigeminal neuralgia due to multiple sclerosis. Acta Neurochir. 2000;142:685–9.CrossRefGoogle Scholar
  15. 15.
    Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology. 1995;45:1294–6.CrossRefGoogle Scholar
  16. 16.
    Love S, Gradidge T, Coakham HB. Trigeminal neuralgia due to multiple sclerosis: ultrastructural findings in trigeminal rhizotomy specimens. Neuropathol Appl Neurobiol. 2001;27:238–44.CrossRefGoogle Scholar
  17. 17.
    Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain. 2001;124:2347–60.CrossRefGoogle Scholar
  18. 18.
    Hilton DA, Love S, Gradidge T, Coakham HB. Pathological findings associated with trigeminal neuralgia caused by vascular compression. Neurosurgery. 1994;35:299–303.CrossRefGoogle Scholar
  19. 19.
    Broggi G, Ferroli P, Franzini A, Servello D, Dones I. Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:59–64.CrossRefGoogle Scholar
  20. 20.
    Meaney JF, Watt JW, Eldridge PR, Whitehouse GH, Wells JC, Miles JB. Association between trigeminal neuralgia and multiple sclerosis: role of magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 1995;59:253–9.CrossRefGoogle Scholar
  21. 21.
    Meaney JM, Miles JB. Microvascular decompression for trigeminal neuralgia. J Neurosurg. 1995;83:183–4.CrossRefGoogle Scholar
  22. 22.
    Zakrzewska JM, Linskey ME. Trigeminal neuralgia. BMJ Clin Evid. 2014;pii:1207.Google Scholar
  23. 23.
    Zakrzewska JM, Linskey ME. Trigeminal neuralgia. 2015;350:h1238.CrossRefGoogle Scholar
  24. 24.
    Jawahar R, Oh U, Yang S, Lapane KL. A systematic review of pharmacological pain management in multiple sclerosis. Drugs. 2013;73:1711–22.CrossRefGoogle Scholar
  25. 25.
    Hunter SF, Lim N, Nashville TN. Carbamazepine (CBZ)-induced exacerbation of weakness in severe demyelinating disease. Neurology. 1999;52:135.Google Scholar
  26. 26.
    Lunardi G, Leandri M, Albano C, Cultrera S, Fracassi M, Rubino V, Favale E. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology. 1997;48:1714–7.CrossRefGoogle Scholar
  27. 27.
    Leandri M, Lundardi G, Inglese M, Messmer-Uccelli M, Mancardi GL, Gottlieb A, Solaro C. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol. 2000;247:556–8.CrossRefGoogle Scholar
  28. 28.
    Kangrga I, Jiang MC, Randic M. Actions of (-)-baclofen on rat dorsal horn neurons. Brain Res. 1991;562:265–75.CrossRefGoogle Scholar
  29. 29.
    DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol. 2003;250:542–5.CrossRefGoogle Scholar
  30. 30.
    Pfau G, Brinkers M, Treuheit T, Kretzschmar M, Senturk M, Hachenberg T. Misoprostol as a therapeutic option for trigeminal neuralgia in patients with multiple sclerosis. Pain Med. 2012;13:1377–8.CrossRefGoogle Scholar
  31. 31.
    Montano N, Papacci F, CioniRinaDi B, MarioMeglio B. What is the best treatment of drug-resistant trigeminal neuralgia in patients affected by multiple sclerosis? A literature analysis of surgical procedures. Clin Neurol Neurosurg. 2013;115:567–72.CrossRefGoogle Scholar
  32. 32.
    Zakrzewska JM, Wu J, Brathwaite TS. A systematic review of the management of trigeminal neuralgia in patients with multiple sclerosis. World Neurosurg. 2011;111:291–306.CrossRefGoogle Scholar
  33. 33.
    Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM, American Academy of Neurology Society, European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013–28.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Nitasha Mishra
    • 1
  1. 1.Department of AnaesthesiologyAll India Institute of Medical Sciences (AIIMS)BhubaneswarIndia

Personalised recommendations